checkAd

    EQS-News  145  0 Kommentare Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

    Für Sie zusammengefasst
    • Mainz Biomed presented industry-leading results at ASCO 2024
    • Study data confirmed high sensitivity for CRC and adenomas
    • Pooled study shows consistent performance of mRNA biomarkers

    Issuer: Mainz BioMed N.V. / Key word(s): Study results/Conference
    Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

    03.06.2024 / 14:01 CET/CEST
    The issuer is solely responsible for the content of this announcement.


    Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

    New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia 

    Results from pooled study represents the third consecutive confirmation of the consistently good performance of Mainz Biomed’s mRNA biomarkers to detect CRC and precancerous lesions

    BERKELEY, US – MAINZ, Germany – June 3rd, 2024 — Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, presented pivotal data from its largest cohort to date during a poster presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, Illinois, and online. This data combines results from the ColoFuture and eAArly DETECT studies including additional patients collected since the first reported study results, demonstrating the significance of its innovative screening approach.

    The combined analysis involves 690 clinical subjects from 30 specialized gastroenterology centers across Europe and the United States, including previously unexamined and unreported samples, highlighting the remarkable efficacy of Mainz Biomed's multimodal screening test. This test integrates the Fecal Immunochemical Test (FIT) with proprietary mRNA biomarkers, complemented by an advanced AI and machine learning algorithm. This combination enables precise differentiation among colorectal cancer (CRC), advanced adenomas (AA), non-advanced adenomas, and samples with no pathological findings.

    Presentation Details

    Title: “A Novel, Non-Invasive, Multimodal Screening Test for Early Detection of Precancerous Lesions and Colorectal Cancer Using an Artificial Intelligence-Based Algorithm.”

    Presenter: Dr. D. Kim Turgeon
    Abstract #: 3627
    Poster Bd #:
    #290
    Citation: J Clin Oncol 42, 2024 (suppl 16; abstr 3627)

    Seite 1 von 5


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-News Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 Issuer: Mainz BioMed N.V. / Key word(s): Study results/Conference Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 03.06.2024 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. …

    Schreibe Deinen Kommentar

    Disclaimer